NeuSage

Facial sensory nerve injuries are a pervasive clinical challenge, affecting individuals who suffer trauma, tumor resections, or congenital defects. These injuries often interrupt the complex mesh of afferent fibers that convey nuanced tactile, thermal, and nociceptive information from the periphery to the brain. Standard repair techniques—including nerve grafts, conduits, and direct suturing—aim to reestablish continuity but frequently result in misaligned regeneration, aberrant synkinesis, or incomplete recovery of fine discrimination. Patients may experience persistent numbness, hypersensitivity, or painful dysesthesias that undermine daily activities and psychosocial well-being.

Advances in microsurgical techniques and pharmacologic adjuvants have improved outcomes marginally, yet the intrinsic ability of peripheral nerves to recapitulate high-fidelity signaling patterns remains constrained. There is a critical unmet need for technologies that can directly interface with injured neural pathways, interpret endogenous electrical activity, and replace or augment lost sensory information in a manner that mimics natural physiological encoding.

We believe that restoring the sense of touch is essential to human dignity and autonomy. NeuSage champions a philosophy of inclusive innovation: by sharing methodologies, datasets, and design blueprints openly with the research community, we foster collective progress toward neural restoration. Our manifest commits to transparency in both successes and failures, rigorous validation under peer scrutiny, and equitable access to therapeutic breakthroughs across socioeconomic boundaries.

Guided by principles of bioethical stewardship, we dedicate ourselves to minimizing patient risk, actively engaging stakeholders in the development process, and ensuring that emergent neuromodulation technologies are harnessed for healing rather than harm.

Our mission is to transcend the limitations of conventional nerve repair by engineering a seamlessly implantable interface that stands at the intersection of neuroscience, materials science, and artificial intelligence. We strive to decode the lexicon of action potentials transmitted along facial sensory fibers and to generate stimulus paradigms that replicate natural firing sequences. Through iterative prototyping, preclinical validation, and phased clinical trials, we will deliver a regulated, scalable therapy that restores sensation with clarity, precision, and durability.

By collaborating closely with clinicians, engineers, and patient advocates, we aim to embed safety, usability, and efficacy into every stage of development—ultimately integrating NeuSage into standard-of-care pathways worldwide.

The NeuSage architecture is a four-module system designed to operate within the dynamic environment of living tissue. First, a conformal high-density microelectrode array captures extracellular potentials from residual axon terminals, sampling hundreds of channels at kilohertz rates. Second, a custom preprocessing unit on a miniaturized PCB performs real-time denoising, artifact rejection, and feature extraction—transforming raw waveforms into structured spike-event data. Third, the core computational engine, built around a multi-head attention transformer, processes these events by comparing them against a learned dictionary of physiological firing patterns. This dictionary is trained on large-scale neural datasets spanning diverse sensory modalities and patient populations. Finally, the output module delivers programmable biphasic pulse trains through a matching electrode array to distal nerve segments, effectively reanimating the sensory map.

NeuSage’s closed-loop feedback mechanism continuously adjusts stimulation parameters in response to evoked potentials and external inputs, enabling adaptive plasticity and homeostatic regulation. Integrated wireless telemetry and energy harvesting modules support long-term implantation without compromising patient mobility. Through rigorous bench testing, animal studies, and safety evaluations, NeuSage is positioned to redefine the paradigm of peripheral nerve regeneration.

NeuSage development follows strict IRB protocols, ensuring informed consent, risk/benefit transparency, and equitable patient selection. We collaborate with bioethicists, regulatory agencies, and patient advocacy groups to guide responsible innovation and post-market surveillance.